New Reporting Requirement for the Opioid Overdose Response and Take Home Naloxone Intervention

Summary The Australian Government is conducting a Naloxone access pilot that fully subsidises the cost of Naloxone supplied in specific circumstances. This Information Bulletin outlines the associated data collection and reporting requirements for services that deliver Opioid Overdose Response and Take Home Naloxone Interventions.

Document type Information Bulletin
Document number IB2020_004
Publication date 03 March 2020
Author branch Alcohol and Other Drugs
Branch contact (02) 9391 9251
Review date 03 March 2021
Policy manual Not applicable
File number H20/14001
Status Active
Functional group Clinical/Patient Services - Medical Treatment, Nursing and Midwifery
Corporate Administration - Governance, Information and Data
Applies to Local Health Districts, Specialty Network Governed Statutory Health Corporations, Public Hospitals
Distributed to Public Health System
Audience Administration, Clinical, Allied Health, Medical, Nursing, Dietitian; Drug and Alcohol Staff; HIV and Related Programs
NEW REPORTING REQUIREMENTS FOR THE OPIOID OVERDOSE RESPONSE & TAKE HOME NALOXONE INTERVENTION

PURPOSE

This Information Bulletin is relevant to all services that supply naloxone to clients in compliance with the NSW Opioid Overdose Response & Take Home Naloxone Policy Directive (PD2019_036). This includes Alcohol and Other Drugs services, Needle Syringe Programs and a range of other services.

The Australian Government is conducting a take home naloxone access pilot through the Pharmaceutical Benefits Scheme (‘PBS pilot’). The PBS pilot subsidises the full cost of take home naloxone supplied to people at risk of experiencing or witnessing opioid overdose.

The PBS pilot runs from 1 December 2019 to 28 February 2021 and NSW is participating. From 1 March 2020, NSW Health services supplying take home naloxone for ORTHN interventions can access naloxone through the PBS pilot for free. A PBS prescription is not required.

This Information Bulletin outlines how ORTHN sites must collect and provide legally mandated data for take home naloxone supplied during the PBS pilot.

KEY INFORMATION

The Australian Government has established a legal instrument to outline the legal requirements for participating in the PBS-based pilot – the National Health (Take Home Naloxone Pilot) Special Arrangement 2019.

Any client who is eligible under the NSW Opioid Overdose Response & Take Home Naloxone Policy Directive (PD2019_036) to receive the ORTHN intervention is eligible to receive naloxone supplied via the PBS pilot.

ORTHN sites should continue to order Prenoxad® and Nyxoid® from their hospital pharmacy during the PBS pilot. An Information Bulletin for pharmacy departments outlines reimbursement procedures during the PBS pilot.

Reporting requirements and Portal registration

Under the Special Arrangement, the Australian Government requires that each ORTHN site provides data every month about the naloxone it supplies which has been obtained through the PBS pilot.

An online portal (‘PPA portal’) has been established by the Australian Government. ORTHN sites must use the PPA portal to report data about the naloxone they supply during the PBS pilot.

For each ORTHN intervention provided, de-identified information about the naloxone products supplied must be entered into the PPA portal.

The Opioid Overdose Response & Take Home Naloxone checklist and record of supply state form was amended in February 2020 to include all data collection fields required for the PBS pilot (Attachment 1).
All ORTHN sites must use the amended form for the duration of the PBS pilot. The amended form replaces the form at PD2019_036: Procedures, Appendix A.

Click [here](https://example.com) for:
- information on how ORTHN sites register for the PPA portal;
- PPA portal data entry instruction guide;
- instructions on how to order the amended *Opioid Overdose Response & Take Home Naloxone checklist and record of supply state form*; and
- information about new questions that have been added to the amended state form.

**Data governance**

The PPA portal is administered under the authority of the Australian Government. Approval to release de-identified data from NSW Health to the Australian Government via the PPA portal has been obtained under the *Health Administration Regulation 2015, Public Health Act 2010*, Clause 17(2) – Disclosure of Information ([Attachment 2](#)).

The Australian Government will provide NSW Ministry of Health with data reports from the PPA portal for program monitoring purposes.

In line with the [NSW Health Data Governance Framework (GL2019_002)](https://example.com), a Data Sponsor, Data Custodian and Data Steward have been appointed for this state wide data asset.

**Evaluation of the pilot**

An evaluation of the PBS pilot is planned. There will be some additional client consent and reporting requirements associated with the evaluation once ethics approval has been received.

The PPA portal includes a client consent tick box to register if clients consent or otherwise to having de-identified information used for evaluation purposes.

This box should be left unticked until ORTHN sites have been notified that all ethics approvals are in place.

**Supply quantities**

A maximum of two units of Prenoxad®, or two units of Nyxoïd®, or one of each product, can be supplied to the client on each occasion of service. There are no limits on the number of times an eligible person can receive naloxone.

**ATTACHMENTS**

1. Opioid Overdose Response & Take Home Naloxone amended state form
2. Approval to release de-identified data
Facility: OPIOID OVERDOSE RESPONSE & TAKE HOME NALOXONE (ORTHN) – CHECKLIST AND RECORD OF SUPPLY

COMPLETE ALL DETAILS OR AFFIX PATIENT LABEL HERE

**Health worker checklist**

**Confirm eligibility**
At risk of experiencing opioid overdose and/or
at risk of witnessing opioid overdose
Aged 16 years or over
Able to give informed consent (i.e. not affected by severe intoxication, severe cognitive impairment, or severe active psychological or physical medical condition that impairs informed consent)

If eligibility criteria are not met, the education intervention and naloxone supply cannot be provided.
Revert to usual care.

**Discuss contraindications and precautions**
Contraindication: Allergy/hypersensitivity to naloxone
Precautions: Pregnant or breastfeeding
If issues with contraindications or precautions are identified, describe issues and actions taken:

**Provide Intervention**
Purpose of naloxone and possible adverse events explained
Education provided
Consumer Information Sheet provided
Client has demonstrated an understanding of:
The risks for opioid overdose
The signs of opioid overdose
Actions in the event of an overdose: (i) assess environment: ‘danger’; (ii) check for response; (iii) call ambulance; (iv) administer naloxone; (v) clear airways and perform rescue breathing; (vi) recovery position and stay with person until ambulance arrives; use more naloxone if no response.
What naloxone is, how and when to use it, including time to onset and duration of effects

**Supply Information**
Client reports they have been supplied with naloxone previously
If client has been supplied with naloxone previously, reason for re-supply (select one only):

Previous supply of naloxone was administered to the client
Previous supply of naloxone was administered to another person
Previous supply of naloxone was lost/damaged/past expiry date
Not applicable

Opioid use reported by the client (may select multiple options, or omit if not disclosed):
Opioids prescribed for the client
Other opioids used
No reported opioid use (at risk of witnessing opioid overdose)

1 Assess risks. If concerned or the client is not suitable for the education intervention and supply of naloxone, revert to “usual care” and refer to an appropriate medical officer or Drug and Alcohol Service for further assessment and intervention.

**Client checklist**
I agree to receive this intervention. I understand the risks of overdose, how to identify an overdose, and what to do in the event of an overdose, including the use of naloxone. I have been provided with Consumer Information Sheet and take home naloxone medication.

Client signature: Date:

**Medication (tick):**

- [ ] Prenoxad® pre-filled injection (syringe contains 5 doses)
- [ ] Nyxoid® intranasal (2 devices in a pack, each containing 1 dose)

**Dosage and Route:**
Give 0.4mL of Prenoxad® Injection (to first black line) into the outer thigh or upper arm muscle.
If the person does not respond, repeat dose (to next black line) every 2 to 3 minutes as required.

Insert Nyxoid® device nozzle in nostril. Press firmly on the plunger until it clicks to give the dose. If the person does not respond after 2 to 3 minutes, give the second dose of Nyxoid®, using the second Nyxoid® device, in the other nostril.

**Amount supplied:**

- [ ] ______ syringe(s)
- [ ] ______ pack(s)

**Health worker name:**

**Signature:**

**Health worker designation:**

**Date:**
I, A/Prof Sarah Thackway, Executive Director, Epidemiology and Evidence of the NSW Ministry of Health, pursuant to clause 17(2) of the Health Administration Regulation 2015, hereby approve the release of information described in Schedule 1 below, to Kirsten Buckingham, acting Director, Specialised Supply Section, Dept of Health.

Signed this 24/2 day of 2020 [YEAR]

.................................
A/Prof Sarah Thackway
Executive Director, Epidemiology and Evidence
SCHEDULE 1

De-identified unit record data as follows:

1. A dataset of the THN Pilot Evaluation Data Collection comprising records relating to National Health (Take Home Naloxone Pilot) Special Arrangement 2019 held by the Center for Population Health of the New South Wales Ministry of Health for the period February 2020 to May 2021, including the following fields:

<table>
<thead>
<tr>
<th>Information required</th>
<th>Field type/format</th>
<th>Suggested text for form/portal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of THN supply</td>
<td>Numerical</td>
<td>DD/MM/YYYY</td>
</tr>
<tr>
<td>Access site postcode</td>
<td>Numerical</td>
<td>XXXX</td>
</tr>
<tr>
<td>Access site type</td>
<td>Single choice</td>
<td>Hospital pharmacy, Community pharmacy, State health, NGO health, Other</td>
</tr>
<tr>
<td>THN formulation and quantities</td>
<td>Multiple options possible</td>
<td>Phebra Prenoxad pre-filled syringe (1-2), Mundipharma Nyxoid Intranasal spray (1-2), Pfizer Ampoule (1-2), Juno Ampoule (1-2)</td>
</tr>
<tr>
<td>Consent statement</td>
<td>Single choice</td>
<td>Participant received PIS and consents for de-identified data to be used for evaluation purposes Y N</td>
</tr>
<tr>
<td>Initial supply or refill</td>
<td>Single choice</td>
<td>Have you received this medication before? Initial Refill</td>
</tr>
<tr>
<td>Reason for refill</td>
<td>Single choice</td>
<td>Used THN on self, Used THN on other, Lost/damaged THN N/A</td>
</tr>
<tr>
<td>Participant type</td>
<td>Multiple options possible</td>
<td>At risk of experiencing OD, At risk of witnessing OD</td>
</tr>
<tr>
<td>Source of opioids used</td>
<td>Multiple options possible</td>
<td>Prescribed opioids (e.g. prescribed by your GP for you), Pharmaceutical opioids sourced elsewhere (e.g. morphine, fentanyl), Illicit opioids (e.g. heroin, opium, fentanyl), Witness only (I don't use opioids)</td>
</tr>
<tr>
<td>Other medications/substances in use</td>
<td>Free Text up to xx characters</td>
<td></td>
</tr>
<tr>
<td>Brief education/advice provided</td>
<td>Single choice</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Y N</td>
</tr>
<tr>
<td>Information required</td>
<td>Field type/format</td>
<td>Suggested text for form/portal</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Resources provided</td>
<td>Single choice</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Participant postcode</td>
<td>Numerical</td>
<td>XXXX</td>
</tr>
<tr>
<td>Gender</td>
<td>Single choice</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>Estimated age range</td>
<td>Single choice</td>
<td>Under 18</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18-40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>40-60</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60+</td>
</tr>
<tr>
<td>Staff designation</td>
<td>Free Text</td>
<td></td>
</tr>
</tbody>
</table>